Stuart A. Aaronson
Aaronson made 1962 his bachelor's degree in chemistry from the University of California at Berkeley, and in 1966 in Medicine at the Medical School of the University of California at San Francisco doctorate (MD degree). After that, he was a scholarship at the University of Cambridge and did his residency training ( Internship ) at Moffitt Hospital in San Francisco. From 1967 he was in the area of cancer viruses ( Viral Cancerogenesis ) at the National Institutes of Health, from 1969 as a Senior Staff Fellow and from 1970 to 1977 as head of the Department of Molecular Biology in cancer virus research. After that, he was head of the Laboratory of Cell and Molecular Biology of the National Cancer Institute. He became a Board 1993 ( Chairman ) Oncology ( Oncological Sciences) at Mount Sinai Medical Center ( Derald H. Ruttenberg Director of the Cancer Center ) and there is Jane B. and Jack R. Aron Professor of Neoplastic Diseases.
1984 to 1987 he was scientific advisor to the American Cancer Society. In 1981 he became associate editor of Cancer Research. He is the author of over 530 scientific papers (2010) and holds over 50 patents.
Aaronson reach important discoveries about oncogenes, partly with the help of a cDNA cloning technique developed by him (stable expression cDNA cloning ). So he discovered with colleagues the first normal functioning of an oncogene in v-sis as a growth factor in cellular communication. He discovered erbB2 as increasingly active in breast cancer gene and discovered the specific for epithelial growth factor KGF ( Keratinocyte Growth Factor, FGF7 ) and its role in wound healing, leading to the development of the drug Kepivance ( by Amgen ), for example, led to oral mucositis. He and his colleagues discovered that the protein encoded in proto-oncogenes MET is a receptor for HGF / SF ( Heptatocyte Growth Factor / Scatter Factor).